{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:28Z","timestamp":1791924208511,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bulcan.2024.11.001","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:45:03Z","timestamp":1733442303000},"page":"225-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insuffisance r\u00e9nale aigu\u00eb chez les patients trait\u00e9s par inhibiteur du check-point immunitaire-recommandations communes FITC\/SFNDT"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-5480","authenticated-orcid":false,"given":"Victor","family":"Gueutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Isnard-Bagnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Belliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2024.11.001_bib0235","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2024.11.001_bib0240","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/ckj\/sfac109","article-title":"Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.001_bib0245","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","article-title":"Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference","volume":"100","author":"Lameire","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0250","unstructured":"14-nephrologie_8e-edition_chap14.pdf [Internet]. [cit\u00e9 17\u00a0oct 2022]. Disponible sur\u00a0: http:\/\/cuen.fr\/manuel\/IMG\/pdf\/14-nephrologie_8e-edition_chap14.pdf."},{"issue":"17","key":"10.1016\/j.bulcan.2024.11.001_bib0255","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2217\/imt-2021-0068","article-title":"Association between PD-L1\u00a0inhibitor, tumor site and adverse events of potential immune etiology within the US\u00a0FDA adverse event reporting system","volume":"13","author":"Abdel-Rahman","year":"2021","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.bulcan.2024.11.001_bib0260","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","article-title":"Acute kidney injury in patients treated with anti-programmed death receptor-1\u00a0for advanced melanoma: a real-life study in a single-centre cohort","volume":"36","author":"Stein","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nephro.2019.05.006","article-title":"Immune check point inhibitor-associated renal toxicity","volume":"16","author":"Izzedine","year":"2020","journal-title":"Nephrol Ther"},{"issue":"10","key":"10.1016\/j.bulcan.2024.11.001_bib0270","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/ndt\/gfz262","article-title":"Acute interstitial nephritis: aetiology and management","volume":"36","author":"Schurder","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.001_bib0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4\u00a0antibody\u2013induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2024.11.001_bib0290","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"24","key":"10.1016\/j.bulcan.2024.11.001_bib0295","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2024.11.001_bib0300","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.nephro.2017.01.016","article-title":"Centre de r\u00e9f\u00e9rence des microangiopathies thrombotiques (CNR-MAT). Thrombotic microangiopathies and antineoplastic agents","volume":"13","author":"Grang\u00e9","year":"2017","journal-title":"Nephrol Ther"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0305","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1\u20132","key":"10.1016\/j.bulcan.2024.11.001_bib0310","first-page":"3","article-title":"The path toward the creation of the American Society of Onco-Nephrology (ASON)","volume":"6","author":"Rashidi","year":"2022","journal-title":"J OncoNephrol"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0315","unstructured":"Nesbitt H. American Society of Nephrology. Online Curricula\u00a0\u2013\u00a0Onco-Nephrology [Internet] [cit\u00e9 17\u00a0octobre 2022]. Disponible sur\u00a0: https:\/\/www.asn-online.org\/education\/distancelearning\/curricula\/onco\/."},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.001_bib0320","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jtho.2018.07.003","article-title":"Specialists to the rescue of oncologists for the management of toxicity occurring under combination of anticancer therapies","volume":"13","author":"Chevalier","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.11.001_bib0325","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0330","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0335","doi-asserted-by":"crossref","first-page":"964335","DOI":"10.3389\/fmed.2022.964335","article-title":"The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Moss","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0340","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.001_bib0345","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jcpt.13469","article-title":"Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"17","key":"10.1016\/j.bulcan.2024.11.001_bib0350","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.001_bib0355","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.bulcan.2024.11.001_bib0360","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3390\/jcm11102915","article-title":"Kidney biopsy in patients with cancer along the last decade: a multicenter study","volume":"11","author":"Bolufer","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0365","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"issue":"36","key":"10.1016\/j.bulcan.2024.11.001_bib0370","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0375","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0380","article-title":"Severe pneumonitis refractory to steroids following anti-PD-1\u00a0immunotherapy","volume":"2018","author":"Andruska","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.001_bib0385","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/curroncol28030201","article-title":"Real world outcomes and hepatotoxicity of infliximab in the treatment of steroid-refractory immune-related adverse events","volume":"28","author":"Araujo","year":"2021","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.11.001_bib0390","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/ijms22052326","article-title":"Acute tubulointerstitial nephritis in clinical oncology: a comprehensive review","volume":"22","author":"Mart\u00ednez-Valenzuela","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.001_bib0395","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","volume":"70","author":"G\u00e9rard","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0400","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.001_bib0405","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u00a0\u2013\u00a0associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0410","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.001_bib0415","doi-asserted-by":"crossref","first-page":"e002292","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.11.001_bib0420","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0425","doi-asserted-by":"crossref","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0430","first-page":"156","article-title":"Mycophenolate as primary treatment for immune checkpoint inhibitor induced acute kidney injury in a patient with concurrent immunotherapy-associated diabetes: a case report","volume":"4","author":"Jessel","year":"2021","journal-title":"Clin Oncol Case Rep"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.001_bib0435","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2215\/CJN.01711105","article-title":"Mycophenolate mofetil for the treatment of interstitial nephritis","volume":"1","author":"Preddie","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bulcan.2024.11.001_bib0440","first-page":"6640154","article-title":"Refractory acute interstitial nephritis in the setting of nivolumab therapy","volume":"2021","author":"Faieta","year":"2021","journal-title":"Case Rep Nephrol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0445","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.11.001_bib0450","doi-asserted-by":"crossref","first-page":"sfae127","DOI":"10.1093\/ckj\/sfae127","article-title":"Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis","volume":"17","author":"Shivaraj","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.001_bib0455","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.ajkd.2012.03.014","article-title":"Association of complete recovery from acute kidney injury with incident CKD stage 3\u00a0and all-cause mortality","volume":"60","author":"Jones","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.001_bib0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-022-02428-8","article-title":"Patient outcomes following AKI and AKD: a population-based cohort study","volume":"20","author":"Wang","year":"2022","journal-title":"BMC Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:07:42Z","timestamp":1737562062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124004533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0007455124004533"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insuffisance r\u00e9nale aigu\u00eb chez les patients trait\u00e9s par inhibiteur du check-point immunitaire-recommandations communes FITC\/SFNDT","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}